Biological ageing and healthspan endpoints — evidence across compounds
Every compound the Institute assesses in biological ageing and healthspan endpoints, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in biological ageing and healthspan endpoints, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| EpithalonSynthetic tetrapeptide | Russian observational and small controlled reports describe mortality and functional differences over multi-year follow-up | not extractable to the Institute's standard; allocation and follow-up methodology are not described adequately | Very low | 1 |
| 5-amino-1MQSmall-molecule nicotinamide N-methyltransferase inhibitor | No human trial identified | — | Not rated | 0 |
| CJC-1295Growth-hormone-releasing hormone analogue with… | No randomised human evidence identified | — | Not rated | 0 |
| GHK-CuCopper(II)-complexed tripeptide | No randomised human evidence for any systemic ageing endpoint | — | Not rated | 0 |
| GlutathioneEndogenous tripeptide thiol antioxidant | No randomised evidence for any ageing endpoint | — | Not rated | 0 |
| MOTS-cMitochondrial-derived 16-residue peptide | No randomised controlled human trial identified | — | Not rated | 0 |
| NAD+ (nicotinamide adenine dinucleotide)Endogenous pyridine dinucleotide coenzyme | No randomised controlled human trial of administered NAD+ on any ageing endpoint identified | — | Not rated | 0 |
| SermorelinGrowth-hormone-releasing hormone fragment analogue | No randomised human evidence identified | — | Not rated | 0 |
| ThymalinThymic peptide extract of undefined composition | No assessable evidence identified | — | Not rated | 0 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory biomarkers of ageing. Advances in Gerontology 2020;10(1):1–8. identifier not held by the Institute The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.